

ECRG2 Antibody

Catalog # ASC11386

Product Information

Application	WB, E, IHC-P
Primary Accession	P58062
Other Accession	AAI09386 , 14211875
Reactivity	Human, Mouse, Rat
Host	Chicken
Clonality	Polyclonal
Isotype	IgY
Calculated MW	9232
Concentration (mg/ml)	1 mg/mL
Conjugate	Unconjugated
Application Notes	ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 μ g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ g/mL.

Additional Information

Gene ID	84651
Other Names	Serine protease inhibitor Kazal-type 7, Esophagus cancer-related gene 2 protein, ECRG-2, SPINK7, ECG2
Target/Specificity	SPINK7; ECRG2 antibody is predicted to not cross-react with other ECRG family members
Reconstitution & Storage	ECRG2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Precautions	ECRG2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	SPINK7
Synonyms	ECG2
Function	Probable serine protease inhibitor.
Cellular Location	Secreted.

Background

ECRG2 Antibody: The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.


References

Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. *Biochem. Biophys. Res. Commun.* 2003; 302:904-15.


Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. *Carcinogenesis* 2007; 28:2274-81

Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. *J. Biol. Chem.* 2009; 284:30897-906

Images



Western blot analysis of ECRG2 in human lung tissue lysate with ECRG2 antibody at 1 $\mu\text{g/mL}$ in (A) the absence and (B) the presence of blocking peptide.



Immunohistochemistry of ECRG2 in rat lung tissue with ECRG2 antibody at 5 $\mu\text{g/mL}$.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.